HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection

被引:10
作者
Neukam, Karin [1 ]
Garcia-Rey, Silvia [1 ]
Cifuentes, Celia [1 ]
Macias, Juan [1 ]
Mira, Jose A. [1 ,2 ]
Vazquez, Maria J. [3 ]
Parra-Sanchez, Manuel [1 ]
Palomares, Jose C. [1 ]
Merchante, Nicolas [1 ]
Di Lello, Federico A. [1 ]
Pineda, Juan A. [1 ]
机构
[1] Hosp Univ Valme, Unit Infect Dis & Microbiol, Seville 41014, Spain
[2] Hosp Univ Valme, Dept Internal Med, Seville 41014, Spain
[3] Ctr Penitenciario Sevilla, Med Serv, Alcala De Guadaira 41500, Spain
关键词
Hepatitis C virus; HIV; RNA load; Pegylated interferon; Ribavirin; Polymerase chain reaction; HEPATITIS-C VIRUS; INTERFERON PLUS RIBAVIRIN; ANTIRETROVIRAL THERAPY; PREDICTION; COHORT;
D O I
10.1016/j.antiviral.2012.06.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The influence of HIV coinfection on plasma hepatitis C virus (HCV) RNA load has not been reliably evaluated. We analyzed plasma HCV RNA load in 396 HCV-monoinfected and 467 HIV/HCV-coinfected patients. Median HCV RNA concentrations (interquartile range) in HCV-monoinfected patients were 5.88 (5.3-6.2) log(10) IU/mL versus 5.96 (5.6-6.5) log(10) IU/mL in HIV/HCV-coinfected individuals (p = 0.033) as determined with the Cobas Amplicor Test and 6.06 (5.4-5.7) log(10) IU/mL versus 6.3 (5.5-6.9) log(10) IU/mL (p = 0.026) using the Cobas TaqMan System. The plasma HCV RNA load in patients with HIV infection and undetectable plasmatic HIV RNA was similar to that observed in HCV-monoinfected individuals [6.02 (5.45-6.61) log(10) IU/mL versus 6.01 (5.36-6.59) log(10) IU/mL, respectively (p = 1.0)]. In conclusion, HIV coinfection tends to be associated with higher plasma HCV RNA load, however, the magnitude of the differences is small and this effect can be counterbalanced with antiviral therapy. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:212 / 215
页数:4
相关论文
共 47 条
  • [41] Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
    Liu, Chen-Hua
    Sheng, Wang-Hui
    Sun, Hsin-Yun
    Hsieh, Szu-Min
    Lo, Yi-Chun
    Liu, Chun-Jen
    Su, Tung-Hung
    Yang, Hung-Chih
    Liu, Wen-Chun
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Hung, Chien-Ching
    Kao, Jia-Horng
    SCIENTIFIC REPORTS, 2015, 5
  • [42] Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
    Lin, Yi-Chun
    Li, Shih-Wei
    Ku, Shin-Yen
    Hsieh, Hui-Ting
    Lin, Mei-Hui
    Chang, Shu-Yin
    Wu, Wei-Wei
    Sun, Na-Lee
    Cheng, Shu-Hsing
    Cheng, Chien-Yu
    INFECTION AND DRUG RESISTANCE, 2019, 12 : 937 - 945
  • [43] Genetic variability in the 5′ UTR and NS5A regions of hepatitis C virus RNA isolated from non-responding and responding patients with chronic HCV genotype 1 infection
    Araujo, Flavio M. G.
    Sonoda, Ivan V.
    Rodrigues, Nilton B.
    Teixeira, Rosangela
    Redondo, Rodrigo A. F.
    Oliveira, Guilherme C.
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2008, 103 (06): : 611 - 614
  • [44] Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis
    Laguno Centeno, Montserrat
    Alvarez, Beatriz
    Martinez-Rebollar, Maria
    de la Mora, Lorena
    Prieto, Laura
    de Lazzari, Elisa
    Gonzalez-Cordon, Ana
    Torres, Berta
    Cabello, Alfonso
    Gorgolas, Miguel
    Mallolas, Josep
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2021, 44 (03): : 191 - 197
  • [45] Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials
    Diana L. Shuster
    Rajeev M. Menon
    Bifeng Ding
    Amit Khatri
    Hong Li
    Eric Cohen
    Melissa Jewett
    Daniel E. Cohen
    Jiuhong Zha
    European Journal of Clinical Pharmacology, 2019, 75 : 207 - 216
  • [46] Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials
    Shuster, Diana L.
    Menon, Rajeev M.
    Ding, Bifeng
    Khatri, Amit
    Li, Hong
    Cohen, Eric
    Jewett, Melissa
    Cohen, Daniel E.
    Zha, Jiuhong
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (02) : 207 - 216
  • [47] Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study
    Londono, Maria-Carlota
    Riveiro-Barciela, Mar
    Ahumada, Adriana
    Munoz-Gomez, Raquel
    Roget, Merce
    Devesa-Medina, Maria J.
    Serra, Miguel Angel
    Navascues, Carmen A.
    Baliellas, Carme
    Aldamiz-Echevarria, Teresa
    Gutierrez, Maria L.
    Polo-Lorduy, Benjamin
    Carmona, Isabel
    Benlloch, Salvador
    Bonet, Lucia
    Garcia-Samaniego, Javier
    Jimenez-Perez, Miguel
    Moran-Sanchez, Senador
    Castro, Ngeles
    Delgado, Manuel
    Gea-Rodriguez, Francisco
    Martin-Granizo, Ignacio
    Montes, Maria Luisa
    Morano, Luis
    Castano, Manuel A.
    de los Santos, Ignacio
    Laguno, Montserrat
    Losa, Juan Emilio
    Montero-Alonso, Marta
    Rivero, Antonio
    de Alvaro, Cristina
    Manzanares, Amanda
    Mallolas, Josep
    Barril, Guillermina
    Gonzalez-Parra, Emilio
    Garcia-Buey, Luisa
    PLOS ONE, 2019, 14 (09):